Wada Koichiro, Kamisaki Yoshinori
Department of Pharmacology, Graduate School of Dentistry, Osaka University.
Nihon Rinsho. 2010 Feb;68(2):278-83.
Peroxisome proliferator-activated receptor gamma (PPARgamma) plays critical roles on insulin sensitivity and adipocyte differentiation, and therefore, several agonists such as pioglitazone and rosiglitazone are used as anti-diabetic drugs. In addition to the original use, clinical applications for the therapy of several specific inflammatory diseases such as inflammatory bowel disease and rheumatoid arthritis are expected, because many reports indicated the anti-inflammatory effects of PPARgamma agonists on various animal disease models. In fact, several drugs and compounds are used or under clinical trials for the therapy of rheumatoid arthritis, ulcerative colitis, and other inflammation-related diseases. Further clinical applications for the therapy of intractable or chronic inflammatory diseases will be progressed.
过氧化物酶体增殖物激活受体γ（PPARγ）在胰岛素敏感性和脂肪细胞分化中起关键作用，因此，几种激动剂如吡格列酮和罗格列酮被用作抗糖尿病药物。除了最初的用途外，由于许多报告表明PPARγ激动剂对各种动物疾病模型具有抗炎作用，因此有望将其用于治疗几种特定的炎症性疾病，如炎症性肠病和类风湿性关节炎。事实上，几种药物和化合物正在用于或正在进行类风湿性关节炎、溃疡性结肠炎和其他炎症相关疾病治疗的临床试验。针对难治性或慢性炎症性疾病治疗的进一步临床应用将会取得进展。
